592 related articles for article (PubMed ID: 25443648)
1. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
[TBL] [Abstract][Full Text] [Related]
2. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
3. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy.
Fuccio C; Castellucci P; Schiavina R; Santi I; Allegri V; Pettinato V; Boschi S; Martorana G; Al-Nahhas A; Rubello D; Fanti S
Ann Nucl Med; 2010 Jul; 24(6):485-92. PubMed ID: 20544323
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility and therapeutic impact of PET/CT [
Sánchez N; Valduvieco I; Ribal MJ; Campos F; Casas F; Nicolau C; Salvador R; Mellado B; Jorcano S; Fuster D; Paredes P
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):284-291. PubMed ID: 32467000
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of
Kitajima K; Fukushima K; Yamamoto S; Kato T; Odawara S; Takaki H; Fujiwara M; Yamakado K; Nakanishi Y; Kanematsu A; Nojima M; Hirota S
Nagoya J Med Sci; 2017 Aug; 79(3):387-399. PubMed ID: 28878443
[TBL] [Abstract][Full Text] [Related]
6. Value of
García JR; Compte A; Buxeda M; Mourelo S; Soler M; Blanch A; Valls E; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):197-203. PubMed ID: 32165153
[TBL] [Abstract][Full Text] [Related]
7. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
8. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
9.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
10. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
Fuccio C; Castellucci P; Schiavina R; Guidalotti PL; Gavaruzzi G; Montini GC; Nanni C; Marzola MC; Rubello D; Fanti S
Eur J Radiol; 2012 Aug; 81(8):e893-6. PubMed ID: 22621862
[TBL] [Abstract][Full Text] [Related]
11. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
12. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.
Picchio M; Spinapolice EG; Fallanca F; Crivellaro C; Giovacchini G; Gianolli L; Messa C
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):13-26. PubMed ID: 21932120
[TBL] [Abstract][Full Text] [Related]
13. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparative study of
Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
[TBL] [Abstract][Full Text] [Related]
15. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
16. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
17. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
19. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.
Wondergem M; van der Zant FM; van der Ploeg T; Knol RJ
Nucl Med Commun; 2013 Oct; 34(10):935-45. PubMed ID: 23903557
[TBL] [Abstract][Full Text] [Related]
20. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
Zhou J; Gou Z; Wu R; Yuan Y; Yu G; Zhao Y
Skeletal Radiol; 2019 Dec; 48(12):1915-1924. PubMed ID: 31127357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
